General information
Title
WHO Access to Medicines 2021-2024
ID
XM-DAC-2-10-6759
CRS ID
2021C06759
Start date
End date
Activity status
Implementation
Actor
UN World Health Organisation - voluntary funds WHO_OMS - WHO - PRT
Sector
Health - Basic Health - Basic health care
Aid type
Contributions to multi-donor/single-entity funding mechanism
Fragile state
No
Least developed country
No
Budgetline
54 31 354002 Voluntary pluriannual contributions internat. multi partner organisations
Finance type
GRANT
Tied status
No
Flow type
ODA
Body
General
In brief, although health products for COVID-19 are a priority, ongoing efforts and initiatives to increase access to health products for all conditions must be maintained or even expanded. A key outcome (1.3) under WHO’s Global Programme of Work for 2020‒2023, improved access is fundamental to attaining WHO’s target of one billion more people benefiting from universal health coverage
Results
• Output 1.3.2: Improved and more equitable access to health products through global market shaping and supporting countries to monitor and ensure efficient and transparent
procurement and supply systems.
• Output 1.3.3: Country and regional regulatory capacity strengthened, and supply of qualityassured and safe health products improved, including through prequalification service.
• Output 1.3.4: Research and development agenda defined and research coordinated in line with public health priorities